durlobactam
Jump to navigation
Jump to search
Indications
- ventilator-associated pneumonia (bacterial pneumonia)
- used in combination with sulbactam
- treatment of carbapenem-resistant Acinetobacter baumannii-calcoaceticus complex
Adverse effects
- nephrotoxicity (13%)
More general terms
Component of
References
- ↑ Kaye KS et al Efficacy and safety of sulbactam-durlobactam versus colistin for the treatment of patients with serious infections caused by Acinetobacter baumannii-calcoaceticus complex: a multicentre, randomised, active-controlled, phase 3, non-inferiority clinical trial (ATTACK). Lancet Infectious Diseases 2023. May 11. https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(23)00184-6/fulltext
- ↑ Shapiro AB, Moussa SH, McLeod SM et al Durlobactam, a New Diazabicyclooctane beta-Lactamase Inhibitor for the Treatment of Acinetobacter Infections in Combination With Sulbactam. Front Microbiol. 2021; 12: 709974. PMID 34349751 PMC8328114 Free PMC article
- ↑ Wikipedia: Durlobactam https://en.wikipedia.org/wiki/Durlobactam